About
Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, is engaged in the research and development, production, and sale of bio-medicine products in the People’s Republic of China. It provides bio-medicines, such as vaccines, blood products, and others. The company offers Group A and C meningococcal polysaccharide vaccine for children and adults over the age of 2 years to prevent disease caused by the bacteria named neisseria meningitidis groups A and group C; and haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis, etc. It also provides prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine; Group A, C meningococcal polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia; and Gr
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 13 investors are based in Kunming, Yunnan, China.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Kunming, China
Contact Information
Find more investors like Walvax
Search Investors